SCHEMBL3519004

SCHEMBL3519004

CC(C)CN(Cc1ccc2c(c1)OCCCO2)C(=O)C1CN(Cc2ccccc2OC(F)(F)F)CCO1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 4/20 0.57
KDM4E B2RXH2 2/20 0.37
MCHR1 Q99705 2/20 0.37
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
APOBEC3A P31941 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
FFAR1 O14842 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
PDE2A O00408 1/20 0.34
LMNA P02545 1/20 0.34
EPHX2 P34913 1/20 0.34
DRD4 P21917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3518632 0.91 PROKR2 (0.64) PROKR2KDM4EMCHR1ALDH1A1SMN1; SMN2
SCHEMBL3518689 0.91 PROKR2 (0.64) PROKR2KDM4EMCHR1ALDH1A1SMN1; SMN2
SCHEMBL3523083 0.90 PROKR2 (0.58) PROKR2KDM4EALDH1A1DRD4
SCHEMBL12993123 0.90 PROKR2 (0.62) PROKR2KDM4EMCHR1ALDH1A1SMN1; SMN2
SCHEMBL3516884 0.90 PROKR2 (0.62) PROKR2KDM4EMCHR1ALDH1A1SMN1; SMN2
SCHEMBL3516850 0.89 PROKR2 (0.61) PROKR2KDM4EMCHR1ALDH1A1SMN1; SMN2
SCHEMBL3521313 0.89 PROKR2 (0.61) PROKR2KDM4EMCHR1ALDH1A1SMN1; SMN2
SCHEMBL3516864 0.89 PROKR2 (0.60) PROKR2KDM4EMCHR1ALDH1A1SMN1; SMN2
SCHEMBL3516542 0.89 PROKR2 (0.60) PROKR2KDM4EMCHR1ALDH1A1SMN1; SMN2
SCHEMBL3520285 0.87 PROKR2 (0.59) PROKR2KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 EP claimed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US claimed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US claimed
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 EP disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists PROKR2, PROKR1, NTSR2 PROKR2 1/4885KDM4E 4734/4885MCHR1 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.